Pratik Choudhary

List of Publications by Year
in descending order

156 papers	5,175 citations	117625 34 h-index	102487 66 g-index
161 all docs	161 docs citations	161 times ranked	4774 citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia, 2007, 50, 1140-1147.	6.3	803
2	Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups. Diabetes Technology and Therapeutics, 2011, 13, 921-928.	4.4	279
3	Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia. Diabetes Care, 2015, 38, 1016-1029.	8.6	192
4	The diet‐derived short chain fatty acid propionate improves beta‐cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes, Obesity and Metabolism, 2017, 19, 257-265.	4.4	186
5	Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia: Figure 1. Diabetes Care, 2011, 34, 2023-2025.	8.6	170
6	Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care, 2017, 40, 63-68.	8.6	141
7	Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes and Endocrinology,the, 2014, 2, 701-709.	11.4	140
8	Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care, 2013, 36, 4160-4162.	8.6	139
9	Interventions That Restore Awareness of Hypoglycemia in Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care, 2015, 38, 1592-1609.	8.6	119
10	Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management. Diabetes Technology and Therapeutics, 2016, 18, 288-291.	4.4	107
11	Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 Diabetes: Evidence from a clinical audit. Diabetes Care, 2009, 32, 1196-1198.	8.6	97
12	Hybrid closed‐loop therapy: Where are we in 2021?. Diabetes, Obesity and Metabolism, 2021, 23, 655-660.	4.4	88
13	A Psychoeducational Program to Restore Hypoglycemia Awareness: The DAFNE-HART Pilot Study. Diabetes Care, 2014, 37, 863-866.	8.6	85
14	Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 462-472.	11.4	84
15	Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop. Transplant International, 2018, 31, 343-352.	1.6	80
16	Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. Diabetic Medicine, 2010, 27, 666-672.	2.3	75
17	Defining Outcomes for β-cell Replacement Therapy in the Treatment of Diabetes. Transplantation, 2018, 102, 1479-1486.	1.0	75
18	Optimal prandial timing of bolus insulin in diabetes management: a review. Diabetic Medicine, 2018, 35, 306-316.	2.3	75

#	Article	IF	Citations
19	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	69
20	Report from IPITA-TTS Opinion Leaders Meeting on the Future of Î²-Cell Replacement. Transplantation, 2016, 100, S1-S44.	1.0	66
21	Effectiveness of Automated Insulin Management Features of the MiniMed^{Â®} 640G Sensor-Augmented Insulin Pump. Diabetes Technology and Therapeutics, 2016, 18, 657-663.	4.4	65
22	Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, S-55-S-61.	4.4	60
23	Attainment of Metabolic Goals in the Integrated UK Islet Transplant Program With Locally Isolated and Transported Preparations. American Journal of Transplantation, 2013, 13, 3236-3243.	4.7	55
24	Mesenchymal stromal cells improve human islet function through released products and extracellular matrix. Clinical Science, 2017, 131, 2835-2845.	4.3	55
25	Virus-like infection induces human Î² cell dedifferentiation. JCI Insight, 2018, 3, .	5.0	53
26	Who gains clinical benefit from using insulin pump therapy? A qualitative study of the perceptions and views of health professionals involved in the Relative Effectiveness of Pumps over <scp>MDI</scp> and Structured Education (<scp>REPOSE</scp>) trial. Diabetic Medicine, 2016, 33, 243-251.	2.3	51
27	Sustained benefit of continuous subcutaneous insulin infusion on glycaemic control and hypoglycaemia in adults with Type 1 diabetes. Diabetic Medicine, 2015, 32, 1453-1459.	2.3	49
28	Distal technologies and type 1 diabetes management. Lancet Diabetes and Endocrinology,the, 2018, 6, 143-156.	11.4	49
29	Evolution and resolution of human brain perfusion responses to the stress of induced hypoglycemia. NeuroImage, 2010, 53, 584-592.	4.2	42
30	Hypoglycaemia: current management and controversies. Postgraduate Medical Journal, 2011, 87, 298-306.	1.8	40
31	Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin. Diabetes, Obesity and Metabolism, 2022, 24, 599-608.	4.4	39
32	Continuous glucose monitoring in patients with insulinoma. Clinical Endocrinology, 2008, 68, 912-918.	2.4	38
33	Hypoglycaemia in type 1 diabetes: technological treatments, their limitations and the place of psychology. Diabetologia, 2018, 61, 761-769.	6.3	38
34	Evaluating Rate of Change as an Index of Glycemic Variability, Using Continuous Glucose Monitoring Data. Diabetes Technology and Therapeutics, 2011, 13, 631-636.	4.4	37
35	Severe hypoglycaemia in type 1 diabetes mellitus: underlying drivers and potential strategies for successful prevention. Diabetes/Metabolism Research and Reviews, 2014, 30, 175-190.	4.0	36
36	Structure-functional changes in eNAMPT at high concentrations mediate mouse and human beta cell dysfunction in type 2 diabetes. Diabetologia, 2020, 63, 313-323.	6.3	34

#	Article	IF	Citations
37	Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID‐19 global pandemic. Diabetic Medicine, 2021, 38, e14433.	2.3	34
38	Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions. Diabetes Technology and Therapeutics, 2015, 17, 801-807.	4.4	33
39	Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care. Diabetes, Obesity and Metabolism, 2019, 21, 2599-2608.	4.4	33
40	Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of Î²-Cell Replacement. Transplantation, 2016, 100, e25-e31.	1.0	32
41	Acceptability of Robot Assistant in Management of Type 1 Diabetes in Children. Diabetes Technology and Therapeutics, 2016, 18, 551-554.	4.4	31
42	Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 2018, 61, 66-74.	6.3	30
43	Hypoglycaemia Awareness Restoration Programme for People with Type 1 Diabetes and Problematic Hypoglycaemia Persisting Despite Optimised Self-care (HARPdoc): protocol for a group randomised controlled trial of a novel intervention addressing cognitions. BMJ Open, 2019, 9, e030356.	1.9	30
44	A Type 1 diabetes technology pathway: consensus statement for the use of technology in Type 1 diabetes. Diabetic Medicine, 2019, 36, 531-538.	2.3	29
45	Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future. Diabetes Therapy, 2021, 12, 2289-2310.	2.5	28
46	Improving management of type 1 diabetes in the UK: the Dose Adjustment For Normal Eating (DAFNE) programme as a research test-bed. A mixed-method analysis of the barriers to and facilitators of successful diabetes self-management, a health economic analysis, a cluster randomised controlled trial of different models of delivery of an educational intervention and the potential of insulin pumps and additional educator input to improve outcomes. Programme Grants for Applied Research, 2014, 2, 1-188.	1.0	28
47	Reducing the burden of hypoglycaemia in people with diabetes through increased understanding: design of the Hypoglycaemia REdefining SOLutions for better liVEs (Hypo‐RESOLVE) project. Diabetic Medicine, 2020, 37, 1066-1073.	2.3	27
48	Unsupervised home use of an overnight closed‐loop system over 3–4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 452-458.	4.4	26
49	A real‐world study of user characteristics, safety and efficacy of open‐source closed‐loop systems and Medtronic 670G. Diabetes, Obesity and Metabolism, 2021, 23, 1989-1994.	4.4	26
50	A parallel randomised controlled trial of the Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia despite optimised self-care (HARPdoc). Nature Communications, 2022, 13, 2229.	12.8	26
51	Blood Glucose Pattern Management in Diabetes: Creating Order from Disorder. Journal of Diabetes Science and Technology, 2013, 7, 1575-1584.	2.2	24
52	Evaluating the relationships of hypoglycaemia and HbA1c with screening‐detected diabetes distress in type 1 diabetes. Endocrinology, Diabetes and Metabolism, 2018, 1, e00003.	2.4	23
53	Recurrent diabetic ketoacidosis and a brief history of brittle diabetes research: contemporary and past evidence in diabetic ketoacidosis research including mortality, mental health and prevention. Diabetic Medicine, 2019, 36, 1329-1335.	2.3	23
54	Hypoglycaemia detection and prediction techniques: A systematic review on the latest developments. Diabetes/Metabolism Research and Reviews, 2021, 37, e3449.	4.0	23

#	Article	IF	Citations
55	Review of dietary recommendations for diabetes mellitus. Diabetes Research and Clinical Practice, 2004, 65, S9-S15.	2.8	22
56	Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology, 2018, 12, 634-638.	2.2	22
57	Health-care professional opinions of DIY artificial pancreas systems in the UK. Lancet Diabetes and Endocrinology,the, 2020, 8, 186-187.	11.4	22
58	Dynamic Profiling of Insulin Secretion and ATP Generation in Isolated Human and Mouse Islets Reveals Differential Glucose Sensitivity. Cellular Physiology and Biochemistry, 2017, 44, 1352-1359.	1.6	21
59	Challenges in glucoCEST MR body imaging at 3 Tesla. Quantitative Imaging in Medicine and Surgery, 2019, 9, 1628-1640.	2.0	21
60	Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.2	20
61	Multiple Daily Injections OR Insulin Pump Therapy: Choosing the Best Option for Your Patientâ€"An Evidence-based Approach. Current Diabetes Reports, 2015, 15, 81.	4.2	20
62	Poorer glycaemic control in type 1 diabetes is associated with reduced self-management and poorer perceived health: A cross-sectional study. Diabetes Research and Clinical Practice, 2014, 106, 35-41.	2.8	19
63	The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling. Cellular and Molecular Life Sciences, 2020, 77, 4709-4723.	5.4	19
64	Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact?. Diabetic Medicine, 2013, 30, 914-917.	2.3	18
65	The Challenge of Sustainable Access to Telemonitoring Tools for People with Diabetes in Europe: Lessons from COVID-19 and Beyond. Diabetes Therapy, 2021, 12, 2311-2327.	2.5	18
66	Impaired Awareness of Hypoglycemia Disrupts Blood Flow to Brain Regions Involved in Arousal and Decision Making in Type 1 Diabetes. Diabetes Care, 2019, 42, 2127-2135.	8.6	17
67	Use of sensorâ€integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a realâ€world study in the UK. Diabetic Medicine, 2019, 36, 1100-1108.	2.3	17
68	Characterization of the Effects of Mesenchymal Stromal Cells on Mouse and Human Islet Function. Stem Cells Translational Medicine, 2019, 8, 935-944.	3.3	17
69	Differentiating Hypoglycemia Awareness Status from Hypoglycemia Experience in Tools for Measuring Impaired Awareness of Hypoglycemia. Diabetes Technology and Therapeutics, 2020, 22, 541-545.	4.4	17
70	The impact of islet mass, number of transplants, and time between transplants on graft function in a national islet transplant program. American Journal of Transplantation, 2022, 22, 154-164.	4.7	17
71	Joint British Diabetes Societies for Inpatient Care: clinical guidelines and improving inpatient diabetes care. Diabetic Medicine, 2018, 35, 988-991.	2.3	16
72	The impact of hypoglycaemia awareness status on regional brain responses to acute hypoglycaemia in men with type 1 diabetes. Diabetologia, 2018, 61, 1676-1687.	6.3	16

#	Article	IF	Citations
73	Doâ€itâ€yourself closedâ€loop systems for people living with type 1 diabetes. Diabetic Medicine, 2020, 37, 1977-1980.	2.3	16
74	Investigating the Association Between Diabetes Distress and Self-Management Behaviors. Journal of Diabetes Science and Technology, 2018, 12, 1116-1124.	2.2	15
75	Distal technology interventions in people with diabetes: an umbrella review of multiple health outcomes. Diabetic Medicine, 2020, 37, 1966-1976.	2.3	15
76	InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoringâ€"Study Design. Diabetes Therapy, 2020, 11, 1017-1027.	2.5	15
77	Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulinâ€and sulphonylureaâ€treated Type 2 diabetes. Diabetic Medicine, 2009, 26, 665-672.	2.3	14
78	Outcomes for Adults with Type 1 Diabetes Referred with Severe Hypoglycaemia and/or Referred for Islet Transplantation to a Specialist Hypoglycaemia Service. Hormone and Metabolic Research, 2015, 47, 9-15.	1.5	14
79	Efficacy of Insulin Pump Therapy in Elderly Patients. Diabetes Technology and Therapeutics, 2015, 17, 364-365.	4.4	14
80	Hypoglycemic thalamic activation in type 1 diabetes is associated with preserved symptoms despite reduced epinephrine. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 787-798.	4.3	14
81	A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2021, 37, e3418.	4.0	14
82	Hes3 Is Expressed in the Adult Pancreatic Islet and Regulates Gene Expression, Cell Growth, and Insulin Release. Journal of Biological Chemistry, 2014, 289, 35503-35516.	3.4	13
83	Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. Diabetic Medicine, 2017, 34, 1456-1460.	2.3	13
84	Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application. BMJ Open, 2022, 12, e051651.	1.9	13
85	Relationship Between Interstitial and Blood Glucose During Hypoglycemia in Subjects with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2011, 13, 1121-1127.	4.4	12
86	A systematic review of the effect of prior hypoglycaemia on cognitive function in type 1 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882090601.	3.2	12
87	Disordered eating in women with type 1 diabetes: Continuous glucose monitoring reveals the complex interactions of glycaemia, selfâ€care behaviour and emotion. Diabetic Medicine, 2021, 38, e14446.	2.3	12
88	Hypoâ€METRICS: Hypoglycaemiaâ€"MEasurement, ThResholds and ImpaCtSâ€"A multiâ€country clinical study to define the optimal threshold and duration of sensorâ€detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: The study protocol. Diabetic Medicine, 2022, 39, .	2.3	11
89	Insulin Pump Therapy With Automated Insulin Suspension. JAMA - Journal of the American Medical Association, 2013, 310, 1235.	7.4	10
90	Who Should Be Considered for Islet Transplantation Alone?. Current Diabetes Reports, 2017, 17, 23.	4.2	10

#	Article	IF	Citations
91	Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision. Diabetes, Obesity and Metabolism, 2021, 23, 2446-2454.	4.4	10
92	Individual, healthcare professional and system‐level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and meta‐ethnography. Diabetic Medicine, 2022, 39, e14678.	2.3	10
93	Current provision and HCP experiences of remote care delivery and diabetes technology training for people with type 1 diabetes in the UK during the COVID‐19 pandemic. Diabetic Medicine, 2022, 39, e14755.	2.3	10
94	Evaluation of the Effect of Carbohydrate Intake on Postprandial Glucose in Patients With Type 1 Diabetes Treated With Insulin Pumps. Journal of Diabetes Science and Technology, 2016, 10, 1287-1293.	2.2	9
95	Prolonged activation of human islet cannabinoid receptors in vitro induces adaptation but not dysfunction. BBA Clinical, 2016, 5, 143-150.	4.1	9
96	Type 1 diabetes and fasting in Ramadan: time to rethink classification of risk?. Lancet Diabetes and Endocrinology,the, 2020, 8, 656-658.	11.4	9
97	An analytical approach to determine the optimal duration of continuous glucose monitoring data required to reliably estimate time in hypoglycemia. Scientific Reports, 2020, 10, 18180.	3.3	9
98	Supporting people with diabetes during the COVID-19 pandemic without face-to-face appointments. British Journal of Diabetes, 2020, 20, 1-4.	0.2	9
99	Characteristics of adults with type 1 diabetes and treatment-resistant problematic hypoglycaemia: a baseline analysis from the HARPdoc RCT. Diabetologia, 2022, 65, 936-948.	6.3	9
100	Technology to Reduce Hypoglycemia. Journal of Diabetes Science and Technology, 2015, 9, 911-916.	2.2	8
101	A modelling study of the budget impact of improved glycaemic control in adults with Type 1 diabetes in the <scp>UK</scp>. Diabetic Medicine, 2019, 36, 988-994.	2.3	8
102	A roadmap to recovery: ABCD recommendations on risk stratification of adult patients with diabetes in the post‐COVID‐19 era. Diabetic Medicine, 2021, 38, e14462.	2.3	8
103	The psychopathology of recurrent diabetic ketoacidosis: A case–control study. Diabetic Medicine, 2021, 38, e14505.	2.3	8
104	Hypoglycemia Subtypes in Type 1 Diabetes: An Exploration of the Hypoglycemia Fear Survey-II. Diabetes Care, 2022, 45, 538-546.	8.6	8
105	Insulin pump therapy: a practical guide to optimising glycaemic control. Practical Diabetes, 2014, 31, 121.	0.3	7
106	Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes. Diabetes Technology and Therapeutics, 2018, 20, 758-766.	4.4	7
107	Baseline Glucose Variability and Interweek Variability Affects the Time to Stability of Continuous Glucose Monitoring-Derived Glycemic Indices. Diabetes Technology and Therapeutics, 2020, 22, 937-942.	4.4	7
108	ABCD position statement on risk stratification of adult patients with diabetes during COVID-19 pandemic. British Journal of Diabetes, 2021, 21, 123-131.	0.2	7

#	Article	IF	Citations
109	Factors Associated With Glycemic Control During Free-Living Overnight Closed-Loop Insulin Delivery in Children and Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1346-1347.	2.2	6
110	Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient‐level pooled analysis of EDITION 1, 2 and 3. Diabetes, Obesity and Metabolism, 2019, 21, 715-719.	4.4	6
111	Donor insulin use predicts beta‐cell function after islet transplantation. Diabetes, Obesity and Metabolism, 2020, 22, 1874-1879.	4.4	6
112	Protocol for a cluster randomised controlled trial of the DAFNE*plus* (Dose Adjustment For) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 self-management in adults with type 1 diabetes. BMJ Open, 2021, 11, e040438.	1.9	6
113	Personality traits of alexithymia and perfectionism in impaired awareness of hypoglycemia in adults with type 1 diabetes â€" An exploratory study. Journal of Psychosomatic Research, 2021, 150, 110634.	2.6	6
114	Restoration of Hypoglycemia Awareness Alters Brain Activity in Type 1 Diabetes. Diabetes Care, 2021, 44, 533-540.	8.6	6
115	Time-in-range and frequency of continuous glucose monitoring: Recommendations for South Asia. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102345.	3.6	6
116	Association of British Clinical Diabetologists, Diabetes Technology Network UK and Association of Children's Diabetes Clinicians Survey of UK Healthcare Professional Attitudes Towards Open-Source Automated Insulin Delivery Systems. Diabetes Therapy, 2022, 13, 341-353.	2.5	6
117	Redesigning an intensive insulin service for patients with type 1 diabetes: a patient consultation exercise. Patient Preference and Adherence, 2013, 7, 471.	1.8	5
118	Home Urine C-Peptide Creatinine Ratio Can Be Used to Monitor Islet Transplant Function: Figure 1. Diabetes Care, 2014, 37, 1737-1740.	8.6	5
119	Autoreactive T cell profiles are altered following allogeneic islet transplantation with alemtuzumab induction and re-emerging phenotype is associated with graft function. American Journal of Transplantation, 2021, 21, 1027-1038.	4.7	5
120	Toward an Optimal Definition of Hypoglycemia with Continuous Glucose Monitoring. Computer Methods and Programs in Biomedicine, 2021, 209, 106303.	4.7	5
121	Islet cell transplantation: current status in the UK. Practical Diabetes, 2012, 29, 280-285.	0.3	4
122	Modification of Human Islet Preparation: An Effective Approach to Improve Graft Outcome After Islet Transplantation?. Hormone and Metabolic Research, 2015, 47, 72-77.	1.5	4
123	First case of pancreas transplant alone in a patient with diabetes and HIV infection. International Journal of STD and AIDS, 2016, 27, 1350-1353.	1.1	4
124	Future of information technology and telecommunication in type 1 diabetes clinical care: results of an online survey. BMJ Open Diabetes Research and Care, 2019, 7, e000917.	2.8	4
125	Hypoglycaemia in hospital: a preventable killer?. Diabetic Medicine, 2014, 31, 1151-1152.	2.3	3
126	Characterization of pre-transplant psychosocial burden in an integrated national islet transplant program. Islets, 2020, 12, 21-31.	1.8	3

#	Article	IF	Citations
127	Impaired Awareness of Hypoglycemia and Severe Hypoglycemia in Drivers With Diabetes: Insights From the Association of British Clinical Diabetologists Nationwide Audit. Diabetes Care, 2021, 44, e190-e191.	8.6	3
128	Insulin Pump Best Practice Guide from the ABCD Diabetes Technology Network UK. British Journal of Diabetes, 2018, 18, 69-70.	0.2	3
129	T1resources.uk; rated, reviewed, reliable. A co-created website for people affected by type 1 diabetes.. British Journal of Diabetes, 2017, 17, 111.	0.2	3
130	Altered functional connectivity during hypoglycaemia in type 1 diabetes. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1451-1462.	4.3	3
131	Flash glucose monitoring: the story so far and the journey ahead. BMJ Innovations, 0, , bmjinnov-2021-000862.	1.7	3
132	Glycaemic measures for 8914 adult <scp>FreeStyle</scp> Libre users during routine care, segmented by age group and observed changes during the <scp>COVID</scp>â€‘19 pandemic. Diabetes, Obesity and Metabolism, 2022, 24, 1976-1982.	4.4	3
133	Taking training into your own hands. Clinical Medicine, 2010, 10, 349-351.	1.9	2
134	Wired for Obesity?. Diabetes, 2014, 63, 4016-4017.	0.6	2
135	Continuous subcutaneous insulin infusion for type 2 diabetes. Lancet, The, 2014, 384, 1240-1242.	13.7	2
136	Implications of Predictive Low-Glucose Management System in Hybrid of Full Closed Loop System. Diabetes Technology and Therapeutics, 2016, 18, 408-409.	4.4	2
137	The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease. Hormone and Metabolic Research, 2021, 53, 204-206.	1.5	2
138	High incidence of undetected low sensor glucose events among elderly patients with type 2 diabetes more than a decade on after the ACCORD study. Current Medical Research and Opinion, 2022, , 1-8.	1.9	2
139	Generation of post-meal insulin correction boluses in type 1 diabetes simulation models for in-silico clinical trials: More realistic scenarios obtained using a decision tree approach. Computer Methods and Programs in Biomedicine, 2022, 221, 106862.	4.7	2
140	Predicting Factors Associated with Hypoglycemia Reduction with Automated Predictive Insulin Suspension in Patients at High Risk of Severe Hypoglycemia: An Analysis from the SMILE Randomized Trial. Diabetes Technology and Therapeutics, 2020, 22, 681-685.	4.4	1
141	Does nocturnal hypoglycaemia really improve quality of life?. Diabetologia, 2021, 64, 1893-1894.	6.3	1
142	Delivering evidence-based interventions for type 1 diabetes in the virtual world â€" A review of UK practice during the SARS-CoV-2 pandemic. Diabetes Research and Clinical Practice, 2022, 185, 109777.	2.8	1
143	The use of technology to reduce hypoglycemia. Pediatric Endocrinology Reviews, 2010, 7 Suppl 3, 384-95.	1.2	1
144	A Mathematical Formula to Determine the Minimum Continuous Glucose Monitoring Duration to Assess Time-in-ranges: Sensitivity Analysis Over the Parameters. , 2021, 2021, 1435-1438.		1

#	Article	IF	Citations
145	Choosing the duration of continuous glucose monitoring for reliable assessment of time in range: A new analytical approach to overcome the limitations of correlation‑based methods. Diabetic Medicine, 2021, , e14758.	2.3	1
146	Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 Diabetes: Evidence from a Clinical Audit: Response to Graveling and Frier. Diabetes Care, 2010, 33, e16-e16.	8.6	0
147	Modern technologies for glucose monitoring and insulin replacement. Medicine, 2014, 42, 703-706.	0.4	0
148	Hypoglycemia as a Function of HbA1c in Type 2 Diabetes (T2DM): Insulin Glargine 300‰U/mL in a Patient-Level Meta-Analysis of EDITION 1, 2 and 3Image 2. Canadian Journal of Diabetes, 2016, 40, S47.	0.8	0
149	To pump or not to pump. Practical Diabetes, 2019, 36, 219-221.	0.3	0
150	Treatment of type 1 diabetes complicated by problematic hypoglycemia. , 2020, , 391-406.		0
151	Letter to the editor. Diabetic Medicine, 2021, 38, e14546.	2.3	0
152	ABCD, DTN-UK, and YDEF News. British Journal of Diabetes, 2021, 21, 158-168.	0.2	0
153	Hypoglycaemia in the treatment of diabetes mellitus. , 2011, , 1849-1861.		0
154	ABCD News. British Journal of Diabetes, 2020, 20, 172-178.	0.2	0
155	ABCD News. British Journal of Diabetes, 2021, 21, 298-306.	0.2	0
156	Methods of Assessment of Counterregulation to Hypoglycaemia. , 0, , 77-103.		0